BDO's 2025 PE survey found 84% of fund managers dealing with extended hold periods. More than 4,000 US portfolio companies are past five years with no exit in sight. I'm not a PE operating partner. But I've spent the last several years working with the founders and revenue leaders inside those portfolio companies — the ones who get handed a 100-day plan and told to accelerate revenue before anyone has diagnosed why revenue stalled in the first place.
What I've observed from that seat is worth naming directly.
The 100-Day Plan Problem Is a Sequencing Problem
Every portfolio company I've worked with that was struggling commercially had the same structural issue: the plan came before the diagnosis. A new CRO gets hired. The org chart gets redrawn. Revenue targets get set. And the underlying confusion — who is actually the right customer, why the sales motion isn't repeatable, why the same objections keep killing deals — goes unexamined because the plan was already committed.
GTM Partners and Blue Ridge Partners both flag this in their 2025–2026 practitioner guides. I flag it because I've watched it happen at the company level, repeatedly. The bottleneck isn't visible in the numbers until the hold period has already extended.
I can't tell you what it's like to sit in an LP review defending a portfolio. I can tell you what it looks like when a revenue leader inside a portfolio company has no structured read on why their pipeline is soft — and has to explain it to a board that expected different results.
Margin Without Revenue Legibility Is a Partial Answer
BCG's 100-Day Cost Reset positions AI-enabled zero-based redesign as the standard opening move for PE margin improvement. The margin math is real. But a portfolio company that has been optimized for cost and cannot demonstrate a repeatable, defensible sales motion still trades at a discount at exit. Buyers underwrite revenue quality — ICP clarity, customer base defensibility, sales motion repeatability — not just EBITDA.
Operating partners who treat cost and GTM as sequential — cost first, revenue second — leave multiple on the table. I've seen this from the inside. The companies that compound value during extended hold periods are the ones that instrument the commercial function early, not 18 months before exit.
What I Built Andru to Do — and Where It Fits
Andru is built for founders and revenue leaders who need to diagnose and govern their commercial motion without adding headcount or hiring a consulting firm. ICP clarity, pipeline quality, positioning coherence, sales motion repeatability — these are diagnosable. We built structured instruments to surface them.
I'll be direct about what Andru is not: it's not a PE portfolio management platform. It's not built for operating partners who need cross-portfolio dashboards. What it does is give the revenue leader inside a single portfolio company a structured, recurring read on commercial health — the kind of evidence that can travel into a board review without requiring a translator.
If you're an operating partner trying to standardize GTM diagnostics across holdings, Andru is one piece of that — the piece that lives inside each company and produces comparable output. The portfolio-level aggregation is a conversation worth having, but I won't pretend we've solved that end-to-end.
The Concrete Moves That Actually Help
Run the diagnostic before the plan. ICP clarity, pipeline coverage, and positioning coherence are diagnosable in weeks. The 100-day plan should follow the diagnosis, not precede it. This is not complicated — it's just sequencing discipline that most plans skip.
Treat GTM instrumentation as a hold-period asset. Every quarter of structured commercial data is a quarter of evidence that compounds toward exit. Buyers underwrite trajectory. A company that can show 18 months of improving ICP clarity and pipeline quality tells a different story than one that can only show a snapshot.
Separate the cost reset from the revenue build — but run them in parallel. The operating partners who are navigating extended hold periods well are running both tracks simultaneously. Waiting on revenue until the cost work is done is a bet that the market will be forgiving. In the current environment, that bet is losing more often than it's winning.
I'm not going to claim Andru solves the exit backlog. What I can say is that the companies I've worked with that have the clearest commercial diagnostics are the ones that have the easiest time making the case for their value — to boards, to buyers, to anyone who needs to understand why the revenue is real and repeatable.
That's the job. The tools should make it easier, not harder.